These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33493079)

  • 1. Development and characterization of pluronic lecithin organogel containing fluocinolone acetonide.
    Patel D; Patel V
    Drug Dev Ind Pharm; 2021 Mar; 47(3):377-384. PubMed ID: 33493079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and in vitro evaluation of a pluronic lecithin organogel containing ricinoleic acid for transdermal delivery.
    Boddu SH; Bonam SP; Wei Y; Alexander K
    Int J Pharm Compd; 2014; 18(3):256-61. PubMed ID: 25306775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation and evaluation of novel controlled release of topical pluronic lecithin organogel of mefenamic acid.
    Jhawat V; Gupta S; Saini V
    Drug Deliv; 2016 Nov; 23(9):3573-3581. PubMed ID: 27494650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and evaluation of tubular micelles of pluronic lecithin organogel for transdermal delivery of sumatriptan.
    Agrawal V; Gupta V; Ramteke S; Trivedi P
    AAPS PharmSciTech; 2010 Dec; 11(4):1718-25. PubMed ID: 21128126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management.
    Hong EJ; Sumanasekera W; Le UM
    Int J Pharm Compd; 2022; 26(1):65-71. PubMed ID: 35081046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propolis organogel as a novel topical delivery system for treating wounds.
    Balata G; El Nahas HM; Radwan S
    Drug Deliv; 2014 Feb; 21(1):55-61. PubMed ID: 24295500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation characterization of lecithin organogel as topical drug delivery system for psoriasis: In-vitro permeation and preclinical evaluation.
    Bule P; Kadkanje P; Kshirsagar R; Puppala ER; Naidu VGM; Chella N
    Drug Dev Res; 2024 May; 85(3):e22191. PubMed ID: 38685610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of a ricinoleic acid poloxamer gel system for transdermal eyelid delivery.
    Boddu SH; Bonam SP; Jung R
    Drug Dev Ind Pharm; 2015 Apr; 41(4):605-12. PubMed ID: 24517574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pluronic lecithin organogel as a topical drug delivery system.
    Pandey M; Belgamwar V; Gattani S; Surana S; Tekade A
    Drug Deliv; 2010 Jan; 17(1):38-47. PubMed ID: 22747074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pluronic lecithin organogel (PLO) of diltiazem hydrochloride: effect of solvents/penetration enhancers on ex vivo permeation.
    Parhi R; Suresh P; Pattnaik S
    Drug Deliv Transl Res; 2016 Jun; 6(3):243-53. PubMed ID: 26754742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, Development and
    Chauhan S; Jhawat V; Singh RP; Yadav A; Garg V
    Recent Adv Drug Deliv Formul; 2024; 18(1):50-60. PubMed ID: 38284692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-Assembling Organogels Based on Pluronic and Lecithin for Sustained Release of Etodolac: In Vitro and In Vivo Correlation.
    Mohammed AM; Faisal W; Saleh KI; Osman SK
    Curr Drug Deliv; 2017; 14(7):926-934. PubMed ID: 27593184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of formulation pH on transdermal penetration of antiemetics formulated in poloxamer lecithin organogel.
    Woodall R; Arnold JJ; McKay D; Asbill CS
    Int J Pharm Compd; 2013; 17(3):247-53. PubMed ID: 24046940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of Pluronic lecithin organogels in the transdermal delivery of drugs.
    Bramwell BL; Williams LA
    Int J Pharm Compd; 2012; 16(1):62-3. PubMed ID: 23050314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the stability of fluoxetine in pluronic lecithin organogel and the determination of an appropriate beyond-use date.
    Peacock GF; Sauvageot J
    Int J Pharm Compd; 2014; 18(3):253-5. PubMed ID: 25306774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the stability of ketoprofen in pluronic lecithin organogel and the determination of an appropriate beyond-use date.
    Peacock GF; Sauvageot J; Addo RT
    Int J Pharm Compd; 2014; 18(4):348-50. PubMed ID: 25474865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gabapentin in Elastic Liposomes: Preparation, Characterization, Drug Release, and Penetration Through Porcine Skin.
    Le UM; Baltzley S; AlGhananeem A
    Int J Pharm Compd; 2018; 22(6):498-503. PubMed ID: 30384350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation and evaluation of lecithin organogel for topical delivery of fluconazole.
    Jadhav KR; Kadam VJ; Pisal SS
    Curr Drug Deliv; 2009 Apr; 6(2):174-83. PubMed ID: 19450224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the stability of promethazine hydrochloride in pluronic lecithin organogel and the determination of an appropriate beyond-use date.
    Peacock GF; Sauvageot J
    Int J Pharm Compd; 2014; 18(4):345-7. PubMed ID: 25474864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Release Tests of Ketoprofen from Pluronic Lecithin Organogel versus Lipoderm Using Immersion Cells and the Phoenix DB-6 Dry Heat Diffusion Tester.
    McKinney RD; Dunbar JR
    Int J Pharm Compd; 2021; 25(3):241-245. PubMed ID: 34125715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.